Thorac Cardiovasc Surg 2021; 69(07): 660-665
DOI: 10.1055/s-0041-1725203
Original Thoracic

Surgery for Pulmonary Metastases: Long-Term Survival in 281 Patients

Wojciech Dudek
1   Department of Thoracic Surgery, University Hospital Erlangen, Erlangen, Germany
2   Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Waldemar Schreiner
1   Department of Thoracic Surgery, University Hospital Erlangen, Erlangen, Germany
2   Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Mohamed Haj Khalaf
1   Department of Thoracic Surgery, University Hospital Erlangen, Erlangen, Germany
2   Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
,
Horia Sirbu
1   Department of Thoracic Surgery, University Hospital Erlangen, Erlangen, Germany
2   Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
› Author Affiliations

Abstract

Background Despite weak evidence, pulmonary metastasectomy (PM) is widely performed with intent to improve patient survival. Our single-institution analysis aims to evaluate outcomes and to identify factors influencing survival of patients undergoing PM for metastases from wide range of primary tumors.

Materials and Methods All patients undergoing curative-intent PM between 2008 and 2018 were retrospectively analyzed. The impact of factors related to primary tumor, metastases, and associated therapy on overall survival (OS) was evaluated using univariable and multivariable Cox proportional hazard models. Cutoff values of continuous variables were determined by a receiver operating characteristic analysis.

Results In this study, 281 patients (178 male, median age 61 years) underwent PM. Two (0.7%) perioperative deaths and 23 (8.2%) major complications occurred. Median interval between the treatment of primary tumor and PM was 21 months. Median size of largest metastasis was 1.4 cm. After the median follow-up of 29 months, 134 patients (47.7%) had died. Five-year OS rate after first PM was 47.1%. Complete resection was achieved in 274 (97.5%) patients. Multivariable analysis identified genitourinary origin (hazard ratio [HR]: 0.30, 95% confidence interval [CI]: 0.15–0.60, p = 0.0008) as independent positive survival prognosticator; incomplete resection (HR: 3.53, 95% CI: 1.40–8.91, p = 0.0077) and age at PM of ≥66 years (HR: 1.97, 95% CI: 1.36–2.85, p = 0.0003) were negative prognosticators.

Conclusion The use of PM as a part of multimodal treatment is in selected population justified. Our analysis identified age, primary tumor origin, and completeness of resection as independent survival prognosticators.



Publication History

Received: 30 November 2020

Accepted: 13 January 2021

Article published online:
11 May 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Van Raemdonck D. Pulmonary metastasectomy: common practice but is it also best practice?. Future Oncol 2015; 11 (2, Suppl): 11-14
  • 2 Dudek W, Schreiner W, Hohenberger W, Klein P, Sirbu H. Forty-two years' experience with pulmonary resections of metastases from colorectal cancer. Thorac Cardiovasc Surg 2017; 65 (07) 560-566
  • 3 Dudek W, Schreiner W, Mykoliuk I, Higaze M, Sirbu H. Pulmonary metastasectomy for sarcoma-survival and prognostic analysis. J Thorac Dis 2019; 11 (08) 3369-3376
  • 4 Dudek W, AlMoussa E, Schreiner W, Mantsopoulos K, Sirbu H. Survival and prognostic analysis after pulmonary metastasectomy for head and neck cancer. Thorac Cardiovasc Surg 2020; DOI: 10.1055/s-0040-1713112.
  • 5 Mohammed TL, Chowdhry A, Reddy GP. et al; Expert Panel on Thoracic Imaging. ACR Appropriateness Criteria® screening for pulmonary metastases. J Thorac Imaging 2011; 26 (01) W1-3
  • 6 Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995; 13 (01) 8-10
  • 7 Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence: the new era of cancer therapy. Jpn J Clin Oncol 2010; 40 (02) 107-111
  • 8 Qi H, Fan W. Value of ablation therapy in the treatment of lung metastases. Thorac Cancer 2018; 9 (02) 199-207
  • 9 Bromham N, Kallioinen M, Hoskin P, Davies RJ. Guideline Committee. Colorectal cancer: summary of NICE guidance. BMJ 2020; 368: m461
  • 10 Pfister DG, Spencer S, Adelstein D. et al. Head and neck cancers: very advanced head and neck cancer. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, Version 1. 2020 . Accessed March 4, 2020 at: https://www.nccn.org/professionals/physician_gls/pdf/headand-neck_blocks.pdf
  • 11 Pastorino U, Buyse M, Friedel G. et al; International Registry of Lung Metastases. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg 1997; 113 (01) 37-49
  • 12 Casiraghi M, De Pas T, Maisonneuve P. et al. A 10-year single-center experience on 708 lung metastasectomies: the evidence of the “International Registry of Lung Metastases”. J Thorac Oncol 2011; 6 (08) 1373-1378
  • 13 Cheung F, Alam N, Wright G. Pulmonary metastasectomy: analysis of survival and prognostic factors in 243 patients. ANZ J Surg 2018; 88 (12) 1316-1321
  • 14 Meacci E, Nachira D, Congedo MT. et al. Lung metastasectomy following kidney tumors: outcomes and prognostic factors from a single-center experience. J Thorac Dis 2017; 9 (Suppl. 12) S1267-S1272
  • 15 Barone M, Prioletta M, Di Nuzzo D, Cipollone G, Camplese P, Mucilli F. Pulmonary metastasectomy in elderly colorectal cancer patients: a retrospective single center study. Updates Surg 2016; 68 (04) 357-367
  • 16 Saleh W, AlShammari A, Sarraj J, AlAshgar O, Ahmed MH, AlKattan K. Surgical treatment of pulmonary metastasis: report from a tertiary care center. Asian Cardiovasc Thorac Ann 2018; 26 (04) 296-301
  • 17 Milosevic M, Edwards J, Tsang D. et al. Pulmonary Metastasectomy in Colorectal Cancer: updated analysis of 93 randomized patients - control survival is much better than previously assumed. Colorectal Dis 2020; 22 (10) 1314-1324